JP7072582B2 - ヨウ素組成物 - Google Patents
ヨウ素組成物 Download PDFInfo
- Publication number
- JP7072582B2 JP7072582B2 JP2019556681A JP2019556681A JP7072582B2 JP 7072582 B2 JP7072582 B2 JP 7072582B2 JP 2019556681 A JP2019556681 A JP 2019556681A JP 2019556681 A JP2019556681 A JP 2019556681A JP 7072582 B2 JP7072582 B2 JP 7072582B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- alkane
- hemifluoride
- iodine
- carrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/20—Halogens; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/69—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine
- A61K8/70—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine containing perfluoro groups, e.g. perfluoroethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Birds (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17167561.4 | 2017-04-21 | ||
| EP17167561 | 2017-04-21 | ||
| PCT/EP2018/060197 WO2018193093A1 (en) | 2017-04-21 | 2018-04-20 | Iodine compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020517622A JP2020517622A (ja) | 2020-06-18 |
| JP2020517622A5 JP2020517622A5 (cg-RX-API-DMAC10.html) | 2021-05-27 |
| JP7072582B2 true JP7072582B2 (ja) | 2022-05-20 |
Family
ID=58672337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556681A Active JP7072582B2 (ja) | 2017-04-21 | 2018-04-20 | ヨウ素組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11273174B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3612228B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7072582B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR102351816B1 (cg-RX-API-DMAC10.html) |
| CN (1) | CN110678207B (cg-RX-API-DMAC10.html) |
| AU (1) | AU2018253944B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3058097C (cg-RX-API-DMAC10.html) |
| ES (1) | ES2957559T3 (cg-RX-API-DMAC10.html) |
| MX (1) | MX388460B (cg-RX-API-DMAC10.html) |
| PL (1) | PL3612228T3 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2018193093A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6039145B2 (ja) | 2011-05-25 | 2016-12-07 | ノバリック ゲーエムベーハー | 半フッ化アルカンを基礎にした局所薬学的組成物 |
| EP2895144B1 (en) | 2012-09-12 | 2017-01-11 | Novaliq GmbH | Semifluorinated alkane compositions |
| US20170087100A1 (en) | 2015-09-30 | 2017-03-30 | Novaliq Gmbh | Semifluorinated compounds and their compositions |
| DK3442480T3 (da) | 2016-06-23 | 2020-01-13 | Novaliq Gmbh | Fremgangsmåde til topisk indgivelse |
| CA3031447A1 (en) | 2016-07-21 | 2018-01-25 | Iogen, Llc | Emollient topical disinfectants |
| KR102614858B1 (ko) | 2016-09-22 | 2023-12-18 | 노바리크 게엠베하 | 안검염 치료에 사용되는 약제학적 조성물 |
| AU2017329983B2 (en) | 2016-09-23 | 2022-05-05 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
| MX381639B (es) | 2016-12-23 | 2025-03-13 | Novaliq Gmbh | Composicion oftalmica para el tratamiento de la enfermedad del ojo seco. |
| PL3612228T3 (pl) | 2017-04-21 | 2024-04-08 | Dermaliq Therapeutics, Inc. | Kompozycje jodu |
| JP7814839B2 (ja) | 2017-09-27 | 2026-02-17 | ノバリック ゲーエムベーハー | 眼疾患の治療に使用するためのラタノプロストを含む眼科用組成物 |
| CN111182893A (zh) | 2017-10-04 | 2020-05-19 | 诺瓦利克有限责任公司 | 包含f6h8的眼用组合物 |
| US11576893B2 (en) | 2018-03-02 | 2023-02-14 | Novaliq Gmbh | Pharmaceutical compositions comprising nebivolol |
| AU2019246035B2 (en) | 2018-03-28 | 2024-07-18 | Novaliq Gmbh | Pharmaceutical composition comprising timolol |
| JP7855312B2 (ja) | 2018-04-27 | 2026-05-08 | ノバリック ゲーエムベーハー | 緑内障の治療のためのタフルプロストを含む眼科用組成物 |
| US11510855B2 (en) | 2018-09-27 | 2022-11-29 | Dermaliq Therapeutics, Inc. | Topical sunscreen formulation |
| WO2020064549A1 (en) * | 2018-09-27 | 2020-04-02 | Novaliq Gmbh | Lipid barrier repair |
| CA3112031A1 (en) | 2018-10-12 | 2020-04-16 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
| CN113164609A (zh) * | 2018-11-27 | 2021-07-23 | 诺瓦利克有限责任公司 | 包含ω-3脂肪酸乙酯的半氟化烷烃组合物 |
| EP3923907B1 (en) | 2019-02-13 | 2024-09-25 | Novaliq GmbH | Compositions and methods for the treatment of ocular neovascularization |
| WO2020239646A1 (en) * | 2019-05-24 | 2020-12-03 | Novaliq Gmbh | Ophthalmic composition for the treatment of ocular allergy |
| CN114449999A (zh) | 2019-09-06 | 2022-05-06 | 诺瓦利克有限责任公司 | 用于治疗葡萄膜炎的眼用组合物 |
| EP3861857A1 (en) * | 2020-02-07 | 2021-08-11 | Novaliq GmbH | Antiparasitic compositions |
| BR112023001995A2 (pt) * | 2020-08-13 | 2023-02-28 | I2Pure Corp | Composições de alta concentração de iodo molecular, formulações farmacêuticas, preparação e usos |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001526647A (ja) | 1997-03-24 | 2001-12-18 | シンボロン・コーポレイション | 眼科用非刺激性ヨウ素医薬および方法 |
| JP2005515235A (ja) | 2002-01-16 | 2005-05-26 | スリーエム イノベイティブ プロパティズ カンパニー | 消毒用組成物および方法 |
| WO2012007776A2 (en) | 2010-07-12 | 2012-01-19 | Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság | Disinfectant and antiseptic formulation having reduced iodine content |
| JP2013540140A (ja) | 2010-10-20 | 2013-10-31 | ノバリック ゲーエムベーハー | 有効成分の送達のための液体医薬組成物 |
| JP2014517841A (ja) | 2011-05-25 | 2014-07-24 | ノバリック ゲーエムベーハー | 半フッ化アルカンを基礎にした局所薬学的組成物 |
Family Cites Families (153)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2616927A (en) | 1950-05-12 | 1952-11-04 | Minnesota Mining & Mfg | Fluorocarbon tertiary amines |
| JPS5721312A (en) | 1980-07-12 | 1982-02-04 | Green Cross Corp:The | Breathable ointment |
| US4452818A (en) | 1982-03-19 | 1984-06-05 | Haidt Sterling J | Extraocular method of treating the eye with liquid perfluorocarbons |
| US5077036A (en) | 1986-01-14 | 1991-12-31 | Alliance Pharmaceutical Corp. | Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid |
| JPH0764702B2 (ja) | 1986-04-23 | 1995-07-12 | 鐘紡株式会社 | 多相乳化型化粧料 |
| JPS6452722A (en) | 1987-05-01 | 1989-02-28 | Anjierini Pharmaceut Inc | Ophthalmic composition |
| JP3046346B2 (ja) | 1990-03-12 | 2000-05-29 | 昭和電工株式会社 | 外用剤基剤又は補助剤とそれを含有する人又は動物の外用剤 |
| US6458376B1 (en) | 1990-09-27 | 2002-10-01 | Allergan, Inc. | Nonaqueous fluorinated drug delivery suspensions |
| US5518731A (en) | 1990-09-27 | 1996-05-21 | Allergan, Inc. | Nonaqueous fluorinated drug delivery vehicle suspensions |
| US5326566A (en) | 1991-05-17 | 1994-07-05 | Bristol-Myers Squibb Company | Use of dibutyl adipate and isopropyl myristate in topical and transdermal products |
| GB9114374D0 (en) | 1991-07-03 | 1991-08-21 | Smithkline Beecham Plc | Novel process |
| US5126127A (en) | 1991-07-16 | 1992-06-30 | Euroceltique, S.A. | Stabilized PVP-I solutions |
| FR2679150A1 (fr) | 1991-07-17 | 1993-01-22 | Atta | Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations. |
| US5336175A (en) | 1992-10-29 | 1994-08-09 | Mames Robert N | Method for the treatment of retinal detachments |
| US5370313A (en) | 1994-01-10 | 1994-12-06 | Beard; Walter C. | Sterile liquid dispenser |
| DE4405627A1 (de) | 1994-02-22 | 1995-08-24 | Hoechst Ag | Fluorkohlenwasserstoffe enthaltende Ölemulsionen |
| FR2720943B1 (fr) | 1994-06-09 | 1996-08-23 | Applic Transferts Technolo | Emulsions inverses stables à forte concentration en composé(s) fluoré(s) et leur utilisation pour l'administration pulmonaire de médicaments et pour la fabrication d'émulsions multiples. |
| US6294563B1 (en) | 1994-10-27 | 2001-09-25 | Allergan Sales, Inc. | Combinations of prostaglandins and brimonidine or derivatives thereof |
| US5464867A (en) * | 1994-11-16 | 1995-11-07 | American Home Products Corporation | Diaminocyclobutene-3,4-diones |
| US5696164A (en) | 1994-12-22 | 1997-12-09 | Johnson & Johnson Consumer Products, Inc. | Antifungal treatment of nails |
| US5874481A (en) | 1995-06-07 | 1999-02-23 | Alliance Pharmaceutical Corp. | Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents |
| US5667809A (en) | 1995-06-07 | 1997-09-16 | Alliance Pharmaceutical Corp. | Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents |
| DE19536504C2 (de) | 1995-09-29 | 1999-09-23 | H Meinert | Verwendung fluorierter Alkane |
| US5874469A (en) | 1996-01-05 | 1999-02-23 | Alcon Laboratories, Inc. | Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs |
| FR2752161B1 (fr) | 1996-08-07 | 1998-09-25 | Atta | Emulsions multiples de type hydrocarbure-dans-eau-dans- fluorocarbone pour le transport de substances medicamenteuses hydrophiles et/ou lipophiles |
| US5863560A (en) | 1996-09-11 | 1999-01-26 | Virotex Corporation | Compositions and methods for topical application of therapeutic agents |
| IN184589B (cg-RX-API-DMAC10.html) | 1996-10-16 | 2000-09-09 | Alza Corp | |
| DE69823852T2 (de) | 1997-02-04 | 2005-05-19 | Johnstone, Murray A., Seattle | Verfahren zur förderung des haarwuchses und entwicklung des haarsystems |
| DE19709704C2 (de) | 1997-03-10 | 1999-11-04 | Michael Georgieff | Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie |
| US5980936A (en) | 1997-08-07 | 1999-11-09 | Alliance Pharmaceutical Corp. | Multiple emulsions comprising a hydrophobic continuous phase |
| US6645963B2 (en) | 1997-11-05 | 2003-11-11 | Senju Pharmaceutical Co., Ltd. | Prolonged-action eye drop |
| US5851544A (en) | 1997-12-18 | 1998-12-22 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Cosmetic skin or hair care compositions containing fluorocarbons infused with carbon dioxide |
| US5981607A (en) | 1998-01-20 | 1999-11-09 | Allergan | Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers |
| CA2278328C (en) | 1998-02-09 | 2008-07-22 | Macrochem Corporation | Antifungal nail lacquer and method using same |
| DE19861012A1 (de) | 1998-03-18 | 1999-09-30 | Pharm Pur Gmbh | Behandlungsmittel für die Ophthalmologie |
| CN1221249C (zh) | 1998-08-19 | 2005-10-05 | 斯凯伊药品加拿大公司 | 普鲁泊福的可注射水分散体 |
| US6140374A (en) | 1998-10-23 | 2000-10-31 | Abbott Laboratories | Propofol composition |
| US6159977A (en) | 1998-11-16 | 2000-12-12 | Astan, Inc. | Therapeutic anti-fungal nail preparation |
| US7258869B1 (en) | 1999-02-08 | 2007-08-21 | Alza Corporation | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle |
| EP1152749B1 (en) | 1999-02-08 | 2006-04-12 | ALZA Corporation | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles |
| WO2000054588A1 (en) | 1999-03-15 | 2000-09-21 | John Claude Krusz | Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages |
| US6177477B1 (en) | 1999-03-24 | 2001-01-23 | American Home Products Corporation | Propofol formulation containing TRIS |
| US6239113B1 (en) | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
| JP2001058734A (ja) | 1999-06-09 | 2001-03-06 | Tohoku Ricoh Co Ltd | 印刷装置 |
| DE19926890C1 (de) | 1999-06-12 | 2000-07-27 | Pharm Pur Gmbh | Verwendung eines hochfluorierten oligomeren Alkans in der Ophthalmologie |
| DE19938668B4 (de) | 1999-08-14 | 2006-01-26 | Bausch & Lomb Inc. | Tränenersatzmittel |
| US6528086B2 (en) | 1999-09-28 | 2003-03-04 | Zars, Inc. | Methods and apparatus for drug delivery involving phase changing formulations |
| US6592907B2 (en) * | 1999-10-04 | 2003-07-15 | Hampar L. Karagoezian | Synergistic antimicrobial ophthalmic and dermatologic preparations containing chlorite and hydrogen peroxide |
| JP2001158734A (ja) | 1999-12-02 | 2001-06-12 | Lion Corp | 眼科用組成物及びソフトコンタクトレンズに対する吸着抑制方法 |
| US20030018044A1 (en) | 2000-02-18 | 2003-01-23 | Peyman Gholam A. | Treatment of ocular disease |
| DE10024413A1 (de) | 2000-05-19 | 2001-12-06 | Mika Pharma Gmbh | Pharmazeutische und/oder kosmetische Zubereitung |
| DE10042412B4 (de) | 2000-08-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System zur Abgabe von Venlafaxin, und seine Verwendung |
| US6399087B1 (en) | 2000-12-20 | 2002-06-04 | Amphastar Pharmaceuticals, Inc. | Propofol formulation with enhanced microbial inhibition |
| WO2002089849A1 (en) | 2001-05-07 | 2002-11-14 | Corium International | Compositions and delivery systems for administration of a local anesthetic agent |
| US20040265362A1 (en) | 2001-09-04 | 2004-12-30 | Rudy Susilo | Plaster for the treatment of dysfunctions and disorders of nail growth |
| JP2005523252A (ja) * | 2002-01-26 | 2005-08-04 | マイクロ サイエンス テック コーポレーション リミテッド | 牧丹皮抽出物を有効成分として含む組成物 |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| EP1663148A2 (en) | 2003-08-25 | 2006-06-07 | Foamix Ltd. | Penetrating pharmaceutical foam |
| US20050079210A1 (en) | 2003-10-09 | 2005-04-14 | Gupta Shyam K. | Liposomal delivery system for topical pharmaceutical, cosmeceutical, and cosmetic ingredients |
| CA2538856C (en) | 2003-10-10 | 2010-06-29 | Antares Pharma Ipl Ag | Transdermal pharmaceutical formulation for minimizing skin residues |
| CA2540621A1 (en) | 2003-11-19 | 2005-06-09 | Barnes-Jewish Hospital | Enhanced drug delivery |
| GB0408164D0 (en) | 2004-04-13 | 2004-05-19 | Immune Targeting Systems Ltd | Antigen delivery vectors and constructs |
| US20080019926A1 (en) | 2004-04-19 | 2008-01-24 | Marie-Pierre Krafft | Lung Surfactant Supplements |
| EP1763336A1 (en) | 2004-06-08 | 2007-03-21 | Ocularis Pharma, Inc. | Hydrophobic ophthalmic compositions and methods of use |
| US7063241B2 (en) | 2004-06-10 | 2006-06-20 | Allergan, Inc. | Dispensing tip |
| AU2005262392A1 (en) | 2004-07-01 | 2006-01-19 | Johnson & Johnson Vision Care, Inc. | Compositions and methods for treating eye disorders and conditions |
| US20060078580A1 (en) | 2004-10-08 | 2006-04-13 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
| US7740875B2 (en) | 2004-10-08 | 2010-06-22 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
| EP1688161A1 (en) | 2004-11-02 | 2006-08-09 | Switch Biotech Aktiengesellschaft | Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis |
| GB0511499D0 (en) | 2005-06-06 | 2005-07-13 | Medpharm Ltd | Topical ungual formulations |
| BRPI0614084A2 (pt) | 2005-08-05 | 2011-03-09 | Bharat Serums And Vaccines Limited | composição estável de emulsão de óleo-em-água de propofol, administrável por via intranovesa; e processo de preparação de uma composição |
| FR2892023B1 (fr) | 2005-10-14 | 2009-09-25 | Galderma Sa | Composition pharmaceutique a base d'amorolfine et d'agent filmogene hydrosoluble pour application ungueale et peri-ungueale |
| DE102005050431A1 (de) | 2005-10-21 | 2007-04-26 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System zur Verabreicherung lipophiler und/oder wenig hautpermeabler Wirkstoffe |
| DE102005055811A1 (de) | 2005-11-23 | 2007-05-31 | Novaliq Gmbh | Verwendung einer Zusammensetzung zur Konservierung von Organen und Gliedmaßen |
| TWI376239B (en) | 2006-02-01 | 2012-11-11 | Andrew Xian Chen | Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof |
| WO2008011836A2 (es) | 2006-07-25 | 2008-01-31 | Osmotica Corp. | Soluciones oftálmicas |
| US20080112895A1 (en) | 2006-08-04 | 2008-05-15 | Insys Therapeutics Inc. | Aqueous dronabinol formulations |
| US20080089923A1 (en) | 2006-09-29 | 2008-04-17 | Burkstrand Michael J | Biodegradable ocular implants and methods for treating ocular conditions |
| US9000048B2 (en) | 2006-11-28 | 2015-04-07 | Wisconsin Alumni Research Foundation | Fluoropolymer-based emulsions for the intravenous delivery of fluorinated volatile anesthetics |
| KR20090087917A (ko) | 2006-12-07 | 2009-08-18 | 썬 파마 어드밴스트 리서치 컴패니 리미티드 | 마이크로리터량의 액체를 방울의 형태로 분배하기 위한 계량된 방울 병 |
| CN200977281Y (zh) | 2006-12-08 | 2007-11-21 | 陈宇 | 带助滴器的滴眼瓶 |
| FR2918891B1 (fr) | 2007-07-20 | 2009-09-25 | Thea Sa Lab | Solution ophtalmique a base de prostaglandines sans conservateur |
| US8222292B2 (en) | 2007-08-06 | 2012-07-17 | Insys Therapeutics, Inc. | Liquid cannabinoid formulations |
| AU2008300013A1 (en) | 2007-09-07 | 2009-03-19 | Qlt Inc. | Drug cores for sustained release of therapeutic agents |
| DE102007055046A1 (de) | 2007-11-19 | 2009-05-28 | Fluoron Gmbh | Infusionslösung |
| PL2110126T3 (pl) | 2008-04-18 | 2012-04-30 | Novaliq Gmbh | Zastosowanie do inhalacji i zakraplania semifluorowanych alkanów jako nośników substancji aktywnych w strefie wewnątrzpłucnej |
| US20100006600A1 (en) | 2008-07-14 | 2010-01-14 | Dascanio Gustavo A | Fluid dispenser including hydrophobic ring |
| US8809261B2 (en) | 2008-10-31 | 2014-08-19 | Elsohly Laboratories, Incorporated | Compositions containing delta-9-THC-amino acid esters and process of preparation |
| US20170044096A1 (en) * | 2013-03-15 | 2017-02-16 | Rutgers, The State University Of New Jersey | Augmenting Moieties for Anti-Inflammatory Compounds |
| JP2012509737A (ja) | 2008-11-26 | 2012-04-26 | サーモディクス，インコーポレイティド | 埋め込み式の眼薬送達器具および眼薬送達方法 |
| JP5670200B2 (ja) * | 2008-12-02 | 2015-02-18 | ロート製薬株式会社 | 眼科用組成物 |
| JP4642905B2 (ja) | 2009-01-22 | 2011-03-02 | 株式会社資生堂 | 乳化化粧料 |
| US8501800B2 (en) | 2009-03-05 | 2013-08-06 | Insite Vision Incorporated | Controlled-release ophthalmic vehicles |
| IT1393419B1 (it) | 2009-03-19 | 2012-04-20 | Medivis S R L | Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6. |
| WO2010146536A1 (en) | 2009-06-18 | 2010-12-23 | Koninklijke Philips Electronics N.V. | Suspension of particles with drug |
| JP5736635B2 (ja) | 2009-06-25 | 2015-06-17 | ライオン株式会社 | ドライアイ治療剤 |
| JP5549669B2 (ja) | 2009-06-25 | 2014-07-16 | ライオン株式会社 | 眼科用組成物、ドライアイ治療剤及びビタミンａの安定化方法 |
| PT2387391T (pt) | 2009-07-24 | 2017-04-20 | Mika Pharma Ges Für Die Entw Und Vermarktung Pharmazeutischer Produkte Mbh | Processo para o desenvolvimento de uma composição líquida a ser aplicada na forma de espuma sobre a pele e composição de aplicação tópica |
| JP2011024841A (ja) | 2009-07-28 | 2011-02-10 | 健太 ▲浜崎▼ | 点眼補助具 |
| EP2332525A1 (en) | 2009-11-23 | 2011-06-15 | Novaliq GmbH | Pharmaceutical composition comprising propofol |
| EP2335735A1 (en) | 2009-12-14 | 2011-06-22 | Novaliq GmbH | Pharmaceutical composition for treatment of dry eye syndrome |
| TWI620569B (zh) | 2009-12-15 | 2018-04-11 | 遠景生物製藥股份有限公司 | 無刺激性眼用聚乙烯吡咯啶酮-碘組成物 |
| US20110223208A1 (en) | 2010-03-09 | 2011-09-15 | Beth Hill | Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations |
| ES2564502T3 (es) | 2010-03-17 | 2016-03-23 | Novaliq Gmbh | Composición farmacéutica para el tratamiento de la presión intraocular aumentada |
| DE102010022567A1 (de) | 2010-06-02 | 2011-12-08 | Fluoron Gmbh | Zubereitung |
| CA2811931C (en) * | 2010-10-20 | 2015-06-16 | Galderma S.A. | Method of treating herpes virus infection using macrocyclic lactone compound |
| US20120100183A1 (en) | 2010-10-23 | 2012-04-26 | Joel Schlessinger | Topical base and active agent-containing compositions, and methods for improving and treating skin |
| EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
| EP2661280B1 (en) | 2011-01-04 | 2018-11-21 | Novaliq GmbH | O/w-emulsions comprising semifluorinated alkanes |
| US20120219640A1 (en) | 2011-02-25 | 2012-08-30 | Wright Kenneth W | Anti-infective solution for athlete's foot |
| CN103561724B (zh) | 2011-05-25 | 2016-06-29 | 诺瓦利克有限责任公司 | 给药给甲的药物组合物 |
| CN202136470U (zh) | 2011-06-08 | 2012-02-08 | 天津市金亿达药用包装材料有限公司 | 便于滴药的眼药瓶 |
| US8758826B2 (en) | 2011-07-05 | 2014-06-24 | Wet Inc. | Cannabinoid receptor binding agents, compositions, and methods |
| TW201808311A (zh) * | 2011-09-16 | 2018-03-16 | 遠景生物製藥股份有限公司 | 安定之普維酮-碘組成物 |
| PT2806886T (pt) | 2012-01-23 | 2017-03-24 | Novaliq Gmbh | Composições de proteínas estabilizadas baseadas em alcanos semifluorados |
| WO2013126602A1 (en) | 2012-02-21 | 2013-08-29 | Massachusetts Eye & Ear Infirmary | Inflammatory eye disorders |
| US9878000B2 (en) | 2012-06-20 | 2018-01-30 | University Of Waterloo | Mucoadhesive nanoparticle composition comprising immunosuppresant and methods of use thereof |
| MX363182B (es) | 2012-09-12 | 2019-03-13 | Novaliq Gmbh | Composiciones que comprenden mezclas de alcanos semifluorados. |
| EP2895144B1 (en) | 2012-09-12 | 2017-01-11 | Novaliq GmbH | Semifluorinated alkane compositions |
| US9278121B2 (en) * | 2013-03-14 | 2016-03-08 | The Board Of Trustees Of The University Of Arkansas | Methods of use for an antimicrobial peptide |
| KR102433489B1 (ko) * | 2013-03-14 | 2022-08-17 | 팬옵티카, 인크. | 눈의 후안부로의 약물 전달을 위한 안구용 제제 |
| EP2783703A1 (en) | 2013-03-25 | 2014-10-01 | B. Braun Melsungen AG | Semifluorocarbon compound containing contrast agent |
| DK3024484T3 (en) | 2013-07-23 | 2018-10-08 | Novaliq Gmbh | STABILIZED ANTIBODY COMPOSITIONS |
| AU2014332488B2 (en) | 2013-10-09 | 2017-03-09 | Johnson Living Trust Dated October 26, 2001, Leonidas A. Johnson, Trustee | Methods and compositions for treating and preventing signs or symptoms of eye disease |
| CN203524843U (zh) | 2013-10-20 | 2014-04-09 | 吕相瑜 | 自助滴眼液辅助支架 |
| WO2015074137A1 (en) | 2013-11-20 | 2015-05-28 | Mary Lynch | Compositions and methods for treatment of ocular inflammation and pain |
| MX376125B (es) | 2014-03-31 | 2025-03-07 | Amcor Rigid Plastics Usa Llc | Recipiente de liberacion controlada. |
| EP4299122A3 (en) * | 2014-05-07 | 2024-03-27 | The Regents of The University of California | Compositions and methods for treating skin and mucous membrane diseases |
| EP2944324A1 (de) | 2014-05-13 | 2015-11-18 | LTS LOHMANN Therapie-Systeme AG | Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen |
| WO2016025560A1 (en) | 2014-08-13 | 2016-02-18 | University Of Florida Research Foundation, Inc. | Preservative removal from eye drops |
| MA41299A (fr) | 2014-12-30 | 2017-11-07 | Axim Biotechnologies Inc | Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite |
| US20170087100A1 (en) | 2015-09-30 | 2017-03-30 | Novaliq Gmbh | Semifluorinated compounds and their compositions |
| EP3722274B1 (en) | 2015-09-30 | 2023-06-07 | Novaliq GmbH | 2-perfluorobutyl pentane for ophthalmic administration |
| DK3442480T3 (da) | 2016-06-23 | 2020-01-13 | Novaliq Gmbh | Fremgangsmåde til topisk indgivelse |
| KR102614858B1 (ko) | 2016-09-22 | 2023-12-18 | 노바리크 게엠베하 | 안검염 치료에 사용되는 약제학적 조성물 |
| AU2017329983B2 (en) | 2016-09-23 | 2022-05-05 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
| CN109803650A (zh) | 2016-09-28 | 2019-05-24 | 诺瓦利克有限责任公司 | 包含大麻素受体结合配体的组合物 |
| WO2018114557A1 (en) | 2016-12-22 | 2018-06-28 | Novaliq Gmbh | Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases |
| MX381639B (es) | 2016-12-23 | 2025-03-13 | Novaliq Gmbh | Composicion oftalmica para el tratamiento de la enfermedad del ojo seco. |
| PL3612228T3 (pl) | 2017-04-21 | 2024-04-08 | Dermaliq Therapeutics, Inc. | Kompozycje jodu |
| US20210069014A1 (en) | 2017-05-06 | 2021-03-11 | Novaliq Gmbh | Drop dispenser |
| US11278503B2 (en) | 2017-05-12 | 2022-03-22 | Novaliq Gmbh | Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions |
| JP7814839B2 (ja) | 2017-09-27 | 2026-02-17 | ノバリック ゲーエムベーハー | 眼疾患の治療に使用するためのラタノプロストを含む眼科用組成物 |
| CN111182893A (zh) | 2017-10-04 | 2020-05-19 | 诺瓦利克有限责任公司 | 包含f6h8的眼用组合物 |
| US11576893B2 (en) | 2018-03-02 | 2023-02-14 | Novaliq Gmbh | Pharmaceutical compositions comprising nebivolol |
| AU2019246035B2 (en) | 2018-03-28 | 2024-07-18 | Novaliq Gmbh | Pharmaceutical composition comprising timolol |
| JP7855312B2 (ja) | 2018-04-27 | 2026-05-08 | ノバリック ゲーエムベーハー | 緑内障の治療のためのタフルプロストを含む眼科用組成物 |
| EP3852734A1 (en) | 2018-09-22 | 2021-07-28 | Novaliq GmbH | Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness |
| US11510855B2 (en) | 2018-09-27 | 2022-11-29 | Dermaliq Therapeutics, Inc. | Topical sunscreen formulation |
| WO2020064549A1 (en) | 2018-09-27 | 2020-04-02 | Novaliq Gmbh | Lipid barrier repair |
| CA3112031A1 (en) | 2018-10-12 | 2020-04-16 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
| CN113164609A (zh) | 2018-11-27 | 2021-07-23 | 诺瓦利克有限责任公司 | 包含ω-3脂肪酸乙酯的半氟化烷烃组合物 |
| CN113518619A (zh) | 2019-01-21 | 2021-10-19 | 诺瓦利克有限责任公司 | 用于治疗眼部新生血管形成的药物组合物 |
-
2018
- 2018-04-20 PL PL18717632.6T patent/PL3612228T3/pl unknown
- 2018-04-20 JP JP2019556681A patent/JP7072582B2/ja active Active
- 2018-04-20 US US16/606,936 patent/US11273174B2/en active Active
- 2018-04-20 AU AU2018253944A patent/AU2018253944B2/en active Active
- 2018-04-20 ES ES18717632T patent/ES2957559T3/es active Active
- 2018-04-20 MX MX2019012604A patent/MX388460B/es unknown
- 2018-04-20 WO PCT/EP2018/060197 patent/WO2018193093A1/en not_active Ceased
- 2018-04-20 EP EP18717632.6A patent/EP3612228B1/en active Active
- 2018-04-20 KR KR1020197034117A patent/KR102351816B1/ko active Active
- 2018-04-20 CA CA3058097A patent/CA3058097C/en active Active
- 2018-04-20 CN CN201880026267.4A patent/CN110678207B/zh active Active
-
2022
- 2022-02-04 US US17/665,313 patent/US12150955B2/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001526647A (ja) | 1997-03-24 | 2001-12-18 | シンボロン・コーポレイション | 眼科用非刺激性ヨウ素医薬および方法 |
| JP2005515235A (ja) | 2002-01-16 | 2005-05-26 | スリーエム イノベイティブ プロパティズ カンパニー | 消毒用組成物および方法 |
| WO2012007776A2 (en) | 2010-07-12 | 2012-01-19 | Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság | Disinfectant and antiseptic formulation having reduced iodine content |
| JP2013540140A (ja) | 2010-10-20 | 2013-10-31 | ノバリック ゲーエムベーハー | 有効成分の送達のための液体医薬組成物 |
| JP2014517841A (ja) | 2011-05-25 | 2014-07-24 | ノバリック ゲーエムベーハー | 半フッ化アルカンを基礎にした局所薬学的組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018253944A1 (en) | 2019-11-07 |
| US20200129543A1 (en) | 2020-04-30 |
| CA3058097C (en) | 2024-01-02 |
| US20220152096A1 (en) | 2022-05-19 |
| BR112019021917A2 (pt) | 2020-05-26 |
| US11273174B2 (en) | 2022-03-15 |
| US12150955B2 (en) | 2024-11-26 |
| AU2018253944B2 (en) | 2022-09-15 |
| CN110678207A (zh) | 2020-01-10 |
| CN110678207B (zh) | 2024-08-02 |
| JP2020517622A (ja) | 2020-06-18 |
| BR112019021917A8 (pt) | 2023-03-21 |
| PL3612228T3 (pl) | 2024-04-08 |
| MX388460B (es) | 2025-03-20 |
| KR20190138866A (ko) | 2019-12-16 |
| ES2957559T3 (es) | 2024-01-22 |
| EP3612228C0 (en) | 2023-08-23 |
| WO2018193093A1 (en) | 2018-10-25 |
| EP3612228B1 (en) | 2023-08-23 |
| KR102351816B1 (ko) | 2022-01-17 |
| CA3058097A1 (en) | 2018-10-25 |
| EP3612228A1 (en) | 2020-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12150955B2 (en) | Iodine compositions | |
| JP2020517622A5 (cg-RX-API-DMAC10.html) | ||
| RU2497516C2 (ru) | Композиция для местного введения | |
| RU2700927C2 (ru) | Офтальмологическая композиция, содержащая циклоспорин и трегалозу | |
| JP6307202B1 (ja) | 新規ヨードフォア組成物および使用方法 | |
| HK1243354A1 (en) | Novel iodophor composition and methods of use | |
| US20220071924A1 (en) | Treatment of ocular diseases with ophthalmic tapinarof compositions | |
| KR101934767B1 (ko) | 신규한 안과용 조성물 및 사용 방법 | |
| JP4758893B2 (ja) | キノロンを含む眼科用組成物及びその使用の方法 | |
| WO2001000226A1 (fr) | Pommade ophtalmique pour traiter les maladies infectieuses | |
| WO2019135779A1 (en) | Novel ophthalmic composition and methods of use | |
| HK40024598B (en) | Iodine compositions | |
| HK40024598A (en) | Iodine compositions | |
| Wróblewska et al. | Design and evaluation of pharmaceutical availability, stability and quality of modified viscosity eye drops with choline salicylate | |
| BR112019021917B1 (pt) | Composições de iodo | |
| JP7250167B2 (ja) | ソフトコンタクトレンズ用医薬組成物 | |
| JP7197726B2 (ja) | ソフトコンタクトレンズ用医薬組成物 | |
| RU2720676C2 (ru) | Глазные капли для лечения возрастной катаракты ядерного вида | |
| RU2595837C2 (ru) | Состав и способ получения глазных капель | |
| JP2023037015A (ja) | ポリヘキサメチレンビグアナイドまたはその塩を含有する水性点眼液 | |
| HK40004464A (en) | Novel ophthalmic composition and methods of use | |
| BR102020001497A2 (pt) | Cloridrato de pilocarpina veiculado em sistema nanocarreador snedds para uso oftalmológico como redutor de pressão intraocular | |
| EP2389069A1 (en) | Methods and compositions for the treatment and prevention of infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210416 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210416 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20210416 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210525 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210824 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210916 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20211203 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220202 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220316 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220412 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220510 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7072582 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |